Molecular Imaging, Inc. is a contract research organization that specializes in the design and execution of in vivo pharmacology and in vivo imaging studies for pharmaceutical and biotechnology customers in the West Coast North America. It offers surgical services for intrasplenic cell, orthotopic mammary fat pad cell, orthotopic pancreatic, orthotopic prostate, orthotopic brain, peritibial cell, and subcutaneous implants, as well as intracardiac injections; and pharmacology discovery services, including determination of max dose tolerance, pharmacokinetic and pharmacodynamic profiling, monitor distribution of targeted biological therapies, cell tracking in vivo, and new model development. T...
800 Technology Drive
Ann Arbor, MI 48108
Founded in 2003
Molecular Imaging, Inc. Finalizes an Agreement to Run a New Preclinical Imaging Center At the Sanford Consortium for Regenerative Medicine in La Jolla, California
Oct 17 13
Molecular Imaging, Inc. announced that it has finalized an agreement to run a new preclinical imaging center at the Sanford Consortium for Regenerative Medicine (Sanford Consortium) in La Jolla, California. The imaging center includes an 11.7T MRI (Bruker), a PET/SPECT/CT (Siemens), IVIS Spectrum bioluminescence (Perkin Elmer) and an ultrasound system (Visual Sonics). The agreement between the Sanford Consortium and MII will allow the CRO to leverage its long history and extensive know-how in preclinical in vivo imaging to serve Sanford Consortium investigators, non-affiliated stem cell researchers, other academic scientists and the pharmaceutical discovery industry. The mission of the Sanford Consortium is to advance stem cell research through collaborative, multi-disciplinary interactions. The consortium enables scientists from the La Jolla Institute for Allergy & Immunology, the Salk Institute for Biological Studies, the Sanford-Burnham Medical Research Institute, The Scripps Research Institute, and the University of California, San Diego to work side by side in a facility specifically designed to for stem cell research. Consistent with the objectives of the California Institute for Regenerative Medicine, Sanford Consortium researchers are applying the powers of stem cells to promote diagnoses, treatments, and cures for degenerative diseases and injuries.
Molecular Imaging, Inc. and Oncotest gmbh Bring the Power of in Vivo Imaging to Patient Derived Tumor Xenografts
Oct 17 13
Molecular Imaging, Inc. and Oncotest GmbH announced that they have entered into a collaboration and co-promotion agreement to apply Molecular Imaging's experience and expertise in in-vivo pre-clinical Imaging to the pioneering Patient Derived Xenograft (PDX) work of Oncotest. Under the terms of the agreement both companies will promote the ability to perform PDX pharmacology studies with 'best in class' in vivo imaging capabilities, allowing researchers in biotechnology and pharmaceutical companies access to imaging endpoints that enhance their decision-making around the selection and development of new oncology drug candidates.